Heterogeneity of Treatment Effects in Schizophrenia

American Journal of Medicine

Volumn 120, Issue 4 SUPPL., 2007, Pages

  Stroup, T Scott ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical Antipsychotic Trials of Intervention Effectiveness; First generation antipsychotics; Heterogeneity of treatment effects; Schizophrenia; Second generation antipsychotics; Treatment pathways

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERVENTION STUDIES; MALE; PATIENT SELECTION; PHARMACOGENETICS; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33947656425     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.005     Document Type: Article

References (11)

1. March J.S., Silva S.G., Compton S., Shapiro M., Califf R., and Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 162 (2005) 836-846
2. Tunis S.R., Stryer D.B., and Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290 (2003) 1624-1632
3. Fleischhacker W.W., and Widschwendter C.G. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other. Curr Opin Psychiatry 19 (2006) 128-134
4. Pandiani J.A., and Banks S.M. Interpreting the results of the CATIE study. Psychiatr Serv 57 (2006) 140-141
5. Luchins D.J. Interpreting the results of the CATIE study. Psychiatr Serv 57 (2006) 139-140
6. Stroup T.S., McEvoy J.P., Swartz M.S., et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29 (2003) 15-31
7. Lieberman J.A., Stroup T.S., McEvoy J.P., et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
8. Haddad P., and Dursun S.M. Selecting antipsychotics in schizophrenia: lessons from CATIE. J Psychopharmacol 20 (2006) 332-334
9. Stroup T.S., Lieberman J.A., McEvoy J.P., et al., CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163 (2006) 611-622
10. McEvoy J.P., Lieberman J.A., Stroup T.S., et al., CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163 (2006) 600-610
11. National Institute of Mental Health. Director's update: NIMH perspective on antipsychotic reimbursement: using results from CATIE [National Institute of Mental Health Website] (2005). http://www.nimh.nih.gov/about/dirupdate_catie.cfm October 28. Available at: http://www.nimh.nih.gov/about/dirupdate_catie.cfm. Accessed March 1, 2007.